Based on the company's recent earnings conference call transcript, the financial analysis reveals several key insights and financial metrics that support an 'underweight' investment stance. 

1. Revenue Growth: The company reported a 4% increase in revenues in the first quarter of fiscal 2017, driven primarily by the pharmaceutical distribution segment. However, the revenue tailwind was slower than expected due to the slowdown in branded drug inflation and the impact of brand and generic drug conversions.

2. Operating Expenses: The company managed its operating expenses effectively, keeping them virtually flat compared to the previous year. However, the projected growth rate for operating expenses has been revised to 4.5% to 6% for the full fiscal year, indicating a potential increase in costs.

3. Adjusted EPS: The adjusted diluted EPS increased by 7% to $1.36 in the first quarter of fiscal 2017, driven by the outstanding performance in the other segment. However, the company's guidance for the full fiscal year reflects a growth rate of 2% to 5%, which suggests a potential slowdown in earnings growth.

4. Share Buybacks: The company purchased $230 million of shares during the quarter and still has $890 million left on its share authorization. However, the management indicated that there would be modest share repurchase activity in the near-term, potentially impacting shareholder value.

5. Revised Fiscal '17 Outlook: The company raised its adjusted EPS guidance to a new range of $5.72 to $5.92, reflecting growth of 2% to 5% versus the previous fiscal year. While the management reaffirmed other financial guidance, the slower revenue ramp and potential increase in operating expenses could impact future earnings.

Overall, although the company demonstrated strong Q1 results, the revised outlook and potential headwinds in revenue growth, operating expenses, and share buybacks suggest a cautionary approach to investment. The potential impact of generic deflation, brand drug pricing, and working capital investment with the largest customer also signal uncertainties that warrant an 'underweight' investment stance.